Skip to content
Evigrade
CriticalClass III antiarrhythmic, selective IKr blocker×Atypical antipsychotic – indole derivative

Updated · Methodology

Mechanism

Ziprasidone itself causes mild to moderate, dose-dependent QT prolongation (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dofetilide is a class III antiarrhythmic. It blocks the rapid potassium current IKr in heart cells, and the higher its plasma concentration, the longer the QT interval (dofetilide label, US Food and Drug Administration, FDA). No studies have been done with ziprasidone and other QT-prolonging drugs, and an additive effect on QT cannot be excluded (ziprasidone SmPC, AEMPS, and label, FDA). About 80% of a dofetilide dose leaves the body in urine, CYP3A4 metabolises it only to a small extent, and dofetilide does not inhibit CYP enzymes (FDA dofetilide label). Ziprasidone has little inhibitory effect on the major CYP enzymes, CYP3A4 included (FDA ziprasidone label), and the documents give no data on how one drug changes the level of the other.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes palpitations, dizziness or fainting and can lead to cardiac arrest. Dofetilide can cause serious ventricular arrhythmias, mainly torsade de pointes, a polymorphic ventricular tachycardia. In trials in people with supraventricular arrhythmias, it occurred in 0.8% of patients, more often at higher doses and mostly in the first three days of treatment (dofetilide label, US Food and Drug Administration, FDA). Palpitations, vertigo, fainting or seizures during ziprasidone treatment may signal a malignant arrhythmia. Post-marketing reports describe infrequent cases of torsade de pointes in people taking ziprasidone who had several risk factors (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Low potassium and magnesium increase the risk of these arrhythmias (ziprasidone SmPC, AEMPS, and dofetilide label, FDA).

Management

The combination is contraindicated. The US ziprasidone label states that ziprasidone should not be given with QT-prolonging drugs and names dofetilide first on this list (ziprasidone label, US Food and Drug Administration, FDA). The Spanish ziprasidone summary of product characteristics (SmPC) contraindicates ziprasidone with QT-prolonging drugs and names class IA and III antiarrhythmics among them. It also contraindicates ziprasidone in arrhythmias treated with these antiarrhythmics. According to its own label, dofetilide is a class III antiarrhythmic (ziprasidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and dofetilide label, FDA). Dofetilide is not authorised in Spain. According to its US label, use with other drugs that prolong the QT interval has not been studied and is not recommended (FDA dofetilide label). Start dofetilide only in a facility that can calculate creatinine clearance, provide continuous electrocardiogram (ECG) monitoring and offer cardiac resuscitation for at least three days. Dofetilide is contraindicated if the QT or corrected QT interval (QTc) is above 440 ms, or above 500 ms in patients with ventricular conduction abnormalities (FDA dofetilide label). Bring potassium into the normal range before starting dofetilide and keep it there throughout treatment (FDA dofetilide label), and correct low potassium and magnesium before starting ziprasidone as well (ziprasidone SmPC, AEMPS). If dofetilide is stopped so that a potentially interacting drug can be given, wait at least two days before starting that drug (FDA dofetilide label). No document gives a waiting time for the opposite switch, only the mean half-life of oral ziprasidone, 6.6 hours (ziprasidone SmPC, AEMPS). Ziprasidone is also contraindicated in known QT prolongation, recent acute myocardial infarction and uncompensated heart failure. If the QTc exceeds 500 ms, the SmPC recommends stopping ziprasidone (ziprasidone SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dofetilide

Other interactions with Ziprasidone